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anville, Pennsylvania; and Ann Arbor, Michigan
rimary percutaneous coronary intervention (PCI) is the pre-
erred reperfusion strategy for patients with ST-segment ele-
ation myocardial infarction (STEMI) if it can be performed
n a timely manner and by experienced operators (1,2). How-
ver, in 2009, primary PCI is still unavailable to many patients
orldwide and in many rural parts of the U.S. (3). Fibrinolytic
herapy is the alternative to primary PCI, but bleeding com-
lications occur in some patients, and as many as 40% are
ltimately resistant to infarct artery reperfusion (4). Among
elected patients who fail to reperfuse with fibrinolytic therapy,
strategy of emergent transfer to a PCI hospital for rescue PCI
as emerged as the standard of care (5). Thus, the definitive
oal in contemporary reperfusion therapy is early, complete,
nd sustained reperfusion, which for decades has been known
o result in better short- and long-term outcomes (6).
See page 102
Given the logistical challenges related to delivering pri-
ary PCI in some settings, investigators have sought to
ombine the best of both reperfusion therapies with early
pstream administration of fibrinolytic therapy, anticoagu-
ants, and antiplatelet agents to establish initial reperfusion,
ollowed by stabilization of the infarct artery with PCI.
acilitated PCI refers to a strategy of PCI performed
outinely and emergently after pharmacological reperfu-
ion—even when pharmacological reperfusion has been
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Cardiovascular Medicine, Geisinger Medical Center,g
anville, Pennsylvania; and the ‡Department of Cardiovascular Medicine, University
f Michigan Medical School, Ann Arbor, Michigan.uccessful. Eighteen trials over 3 decades have examined the
fficacy and safety of this approach (7) but unfortunately
ave failed to show an improvement in clinical outcomes
hen compared with primary PCI. In fact, when full-dose
brinolytic therapy was used for pharmacological reperfu-
ion, an increased rate of bleeding, nonfatal myocardial
nfarction, stroke, and death was observed with facilitated
CI. A criticism of these trials was the relatively short time
ntervals between upstream fibrinolytic therapy and PCI,
hich have been thought to contribute, at least in part, to
dverse events. Given these findings, American and Euro-
ean guidelines have cautioned against the use of facilitated
CI with full-dose fibrinolytic therapy (1,2).
In contrast, trials testing the hypothesis of routine but
onemergent PCI after successful fibrinolytic therapy have
hown benefit when compared with fibrinolytic therapy
hen delays between fibrinolysis and PCI were 3 to 24 h
8,9). This strategy has often been referred to as the
harmacoinvasive approach; the recent TRANSFER-AMI
Trial of Routine Angioplasty and Stenting after Fibrino-
ysis to Enhance Reperfusion in Acute Myocardial Infarc-
ion) is the largest and latest trial to study this approach
10). On average, patients in the pharmacoinvasive arm in
he TRANSFER-AMI trial underwent cardiac catheteriza-
ion and subsequent PCI 3.9 h after receiving full-dose
brinolytic therapy. Significant improvements were noted in
he composite end point of death, reinfarction, recurrent
schemia, new or worsening ischemia, or cardiogenic shock
hen compared with fibrinolytic therapy and delayed car-
iac catheterization. Differences in this end point were
riven largely by reductions in reinfarction, recurrent isch-
mia, and new or worsening heart failure—all events likely
mproved by stabilization of the infarct artery with PCI. No
ifferences were noted between groups in rates of major
leeding or transfusion.
In this issue of the Journal, the NORDISTEMI (NOR-
egian study on DIstrict treatment of ST-Elevation Myo-
ardial Infarction) by Bøhmer et al. (11) takes these findings
step further. In brief, the trial included 266 patients at
ural community hospitals in Norway with expected time
elays for primary PCI 90 min. All patients received
uideline-based therapy with full-dose fibrinolytic therapy
ith tenecteplase and adjunctive therapy with enoxaparin
nd clopidogrel. In addition, 57% of patients received
brinolytic therapy in the pre-hospital setting. Then, pa-
ients were randomly assigned to transfer for planned
ardiac catheterization (n  134) and revascularization as
ndicated or a conservative ischemia-guided protocol (n 
32) at the community hospital with rescue PCI for failed
brinolysis. Median time from fibrinolytic therapy to first
alloon inflation was 2.7 h in the pharmacoinvasive arm.
he primary end point—a composite of death, reinfarction,
troke, or new ischemia at 12 months—occurred in 21% of
he pharmacoinvasive group versus 27% of the conservative
roup (p  0.19). Excluding the softer end point of new
i
r
p
M
g
fi
r
i
r
c
d
c
l
t
m
d
c
r
c
w
s
a
d
a
i
c
p
N
c
P
c
A
e
e
G
o
a
p
t
P
p
a
(
p
f
T
i
r
f
b
p
f
E
a
e
i
p
a
c
l
T
t
s
a
t
l
a
s
A
T
h
a
R
G
M
1
R
112 Buckley and Nallamothu JACC Vol. 55, No. 2, 2010
PCI After Fibrinolysis for STEMI January 12, 2010:111–3schemia, the secondary composite end point of death,
einfarction, or stroke at 12 months was statistically im-
roved in the early invasive arm (6% vs. 16%; p  0.01).
oreover, overall bleeding rates did not differ between
roups despite the relatively short time interval between
brinolysis and PCI, perhaps a result of the high rate of
adial artery access that was used (80%).
Although far from definitive, this study’s findings add
mportantly to a growing body of evidence that supports
outine and nonemergent cardiac catheterization after suc-
essful fibrinolytic therapy. For many hospital systems, the
elay to primary PCI remains a formidable barrier, and the
oncept of using PCI as a nonemergent adjunct to fibrino-
ytic therapy is very appealing. Patients could receive con-
emporary guideline-based fibrinolytic therapy with first
edical contact-to-needle times within 30 min and imme-
iate antiplatelet therapy with clopidogrel. Those without
linical reperfusion could then be emergently referred for
escue PCI, whereas patients with successful reperfusion
ould undergo cardiac catheterization and revascularization
ithin 24 h. Bøhmer et al. (11) suggest that PCI can be
afely delivered as early as 2 to 3 h after fibrinolysis,
lthough earlier treatment might not be superior to longer
elays that are still within a 24-h window. The great
ttraction of this approach is that it would alleviate the
ntensive resource demand required of STEMI systems of
are that attempt to emergently deliver primary PCI to all
atients (12).
An immediate consequence of the TRANSFER-AMI and
ORDISTEMI trials is that clinicians will more strongly
onsider recommending routine cardiac catheterization and
CI after successful fibrinolytic therapy in STEMI patients—
urrently Class IIb and Class IIa recommendations in the
merican and European guidelines, respectively (1,2). How-
ver, the larger implication of these trials is their long-term
ffect on population-based approaches to reperfusion therapy.
iven that the most significant advantages of primary PCI
ver fibrinolytic therapy are related to reductions in reinfarction
nd recurrent ischemia, it is interesting to postulate whether a
harmacoinvasive approach among fibrinolytic-eligible pa-
ients would result in similar outcomes compared with primary
CI when significant delays to primary PCI exist. For exam-
le, the 30-day reinfarction rate between the pharmacoinvasive
nd fibrinolytic therapy arms in the NORDISTEMI trial
1.5% vs. 5.3%) compares favorably with pooled results re-
orted from a meta-analysis evaluating inter-hospital transfer
or primary PCI with fibrinolytic therapy (1.5% vs. 5.1%) (13).
his hypothesis has not been studied definitively in a random-
zed clinical trial, although the large FAST-MI (French
egistry on Acute ST-elevation Myocardial Infarction) registry
rom France suggests that, when fibrinolytic therapy is com-
ined with liberal use of PCI, the results are comparable to
rimary PCI (14). The ongoing STREAM (Strategic Reper-
usion With Tenecteplase and Antithrombotic Treatment
arly After Myocardial Infarction) trial will provide somenswers to this question as well (15).Throughout the world, STEMI systems of care rely on
fficient identification, triage, and delivery of patients to facil-
ties capable of providing timely reperfusion therapy. Although
rimary PCI remains the preferred strategy, timeliness remains
key limitation to its universal use. Given the geographic
hallenges that are present in many parts of the world, this
imitation is unlikely to be overcome in the immediate future.
he approach studied by Bøhmer et al. (11) as well as the trials
hat preceded it offer a potential paradigm shift for STEMI
ystems of care—particularly in rural areas—that combines the
dvantages of fibrinolytic therapy and PCI without the limi-
ations of facilitated PCI. When access to primary PCI is
imited, incorporating timely cardiac catheterization of patients
fter fibrinolysis into STEMI systems of care should be
trongly considered.
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